Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alcon Inc. Investors

< Previous 1 2 Next >
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon to Present at 2025 Baird Global Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Agrees to Acquire STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
Tickers ALC STAA
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces Results of 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Publishes Agenda for 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Agrees to Acquire LENSAR, Inc.
From Alcon Inc. Investors
Via Business Wire
Tickers ALC LNSR
Alcon to Host 2025 Capital Markets Day
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces Results of 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
From Alcon Inc. Investors
Via Business Wire
Tickers ALC
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.